From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Trade names Tracleer
AHFS/ Monograph
MedlinePlus a605001
  • X
Routes of
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 50%
Protein binding >98%
Metabolism Hepatic
Biological half-life 5 hours
CAS Number 147536-97-8 YesY
ATC code C02KX01 (WHO)
PubChem CID 104865
DrugBank DB00559 YesY
ChemSpider 94651 YesY
KEGG D01227 N
ChEBI CHEBI:51450 YesY
Chemical data
Formula C27H29N5O6S
Molar mass 551.614 g/mol
 NYesY (what is this?)  (verify)

Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer.

Medical uses[edit]

Bosentan is indicated mainly for the treatment of pulmonary hypertension. In 2007, Bosentan was also approved in the European Union for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.[citation needed]

In the United States, Bosentan is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class II-IV symptoms, to improve exercise capacity and decrease the rate of clinical worsening.[1]

Side effects[edit]

Due to potential hepatotoxicity, the FDA requires monthly monitoring of liver function tests while taking Bosentan.

Bosentan use requires hematocrit monitoring due to potential onset of anemia.[2]

Hormone-based contraception is not possible in women taking Bosentan, due to a pharmacokinetic interaction.[3] Therefore, other highly reliable forms of contraception should be used instead.

Bosentan is contraindicated in pregnancy because of its teratogenicity (Pregnancy Category X).[4][5]

Mechanism of action[edit]

Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes constriction of the pulmonary blood vessels. By blocking this interaction, bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B.[6]

See also[edit]


  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^ Funke C, Farr M, Werner B, Dittmann S, Uberla K, Piper C, Niehaus K, Horstkotte D (Apr 2010). "Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.". Journal of General Virology. 91 (8): 1959–1570. doi:10.1099/vir.0.020065-0. PMID 20392896. 

External links[edit]